46 results about "ALF - Acute liver failure" patented technology

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and / or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol / high lipids, and various inflammatory diseases and conditions.

A composition comprising a water-soluble and stable complex formed by an alkyl ether derivative of gamma-cyclodextrin and curcumin and optionally comprising non-complexed cyclodextrin, the molar ratio of curcumin to cyclodextrin being between 1:1 and 1:6, and a method of manufacturing such a composition. The water-soluble and stable complex of curcumin is useful in therapy, e.g. for treatment of cancer, leukemia, myocardial infarction, stroke, sepsis, acute lung injury, acute liver failure, acute tubular necrosis, acute pancreatitis, radiation injury and other life-threatening conditions in a human or animal subject, as well as for preserving human or animal organs, tissues or cells at a hypothermic temperature.

The invention provides an exosome from adipose-derived stem cells and a preparation method thereof. The exosome from the adipose-derived stem cells can be used for treating an acute hepatic failure, liver fibrosis, liver cirrhosis and other liver diseases. The exosome from the adipose-derived stem cells can remarkably increase the survival rate of a patient with the acute hepatic failure and evencan realize the 100% survival rate of the patient with the acute hepatic failure under high concentration.

The invention discloses an in vitro construction method of liver organs and applications. Mouse hepatocytes are extracted to induce to construct liver organs; the forms of the liver organs are observed under a microscope; and immunofluorescence and PCR identification are performed on dryness and epithelial cell properties. An acute hepatic failure mouse model after 70% hepatectomy is established;the liver functions on the first, fourth and seventh day after operation are evaluated after the liver organs are transplanted; liver-to-body ratio is compared; and the treatment effects of the liverorgans on acute hepatic failure are verified through HE staining and immunohistochemistry. Inflammations such as HE staining and ki-67 staining and proliferation indexes show that proliferation can beobviously enhanced after the liver organs are transplanted. The liver organs have strong dryness and proliferation functions; the liver functions of acute hepatic failure mice after 70% hepatectomy can be effectively relieved, and the liver-to-body ratio can be increased; and liver regeneration and repair of acute hepatic failure after 70% hepatectomy can be promoted by relieving inflammatory infiltration of livers.

The invention relates to the biomedical field, and particularly relates to application of dihydromyricetin in preparation of a liver treatment and regeneration promotion medicine. Dihydromyricetin shows relatively high oxidation resistance and characteristic on promoting cell growth as a flavonoid compound. The test shows that dihydromyricetin can effectively relieve liver tissue necrosis caused by acute hepatic failure and can promote hepatocyte proliferation, so as to obviously raise the survival rate of a model mouse suffering from acute hepatic failure; dihydromyricetin also can obviously improve the activity of superoxide dismutase in tissue and serum, increase the content of serum protein, and lower down the levels of glutamic oxalacetic transaminase, glutamic-pyruvic transaminase and tumor necrosis factor alpha.

The invention relates to the technical field of biomedical engineering. Liver transplantation is the only effective means that can be employed for treating liver diseases in late stage at present and is greatly limited in clinic use due to lack of liver sources. Hepatic stem cells have a self-updating capacity and a bidirectional differentiation capacity of differentiating into hepatocytes and cholangiocytes and therefore can provide an infinite number of donor cells for hepatocyte transplantation treatment in theory. The method for the transdifferentiation of fibroblasts into hepatic stem cells, which is provided by the invention, is to reprogram fibroblasts into hepatic stem cells which have the unique self-updating and bidirectional differentiation capacities of hepatic stem cells by using three transcription factors, namely c-Jun, Foxa2 and Hnf1beta. The inducible hepatic stem cells prepared by the method can be used as ideal cell sources for cell treatment of acute hepatic failure and liver diseases in medium and late stages, can be used as seed cells for medicine screening and tissue engineering livers and can provide an ideal research platform for researching cell biological characteristics of hepatic stem cells, liver development and the like.

The invention relates to the technical field of new indication of a medicine, and specifically relates to an application of Babaodan in preparing a medicine for preventing and treating acute liver failure. The application of Babaodan in preparing a medicine for acute liver failure designed in the invention is revealed for the first time; the traditional Chinese medicine Babaodan provided by the invention is verified repeatedly by thioacetamide (TAA) induced acute liver failure rat model experiments, and the result proves that the Babaodan can remarkably improve the liver function and relieve the degrees of liver necrosis and liver injury. Therefore, the Babaodan can be used for preparing a medicine for preventing and treating acute liver failure, and has a good prospect in development andapplication.

The invention discloses application of FC-99 shown as a formula (I) in preparing drug for preventing or treating acute hepatic failure, particularly relates to application of FC-99 in inducing expression of Let-7a (microRNA Let-7A) to inhibit occurrence and development of hepatic failure so as to prevent or treat the hepatic failure and belongs to the field of biomedicine. By building an acute hepatic failure mouse animal model induced by D-aminogalactose combined with lipopolysaccharide and intervening fulminant hepatic failure through FC-99, a result shows that FC-99 can obviously lower transaminase, inhibit inflammation factor release, reduce hepatic cell apoptosis and maintain liver microscopic structure stable and can remarkably lower death rate of mice with acute hepatic failure; bioinformatic analysis and molecular biological detection find that FC-99 is realized by inducing high expression of Let-7a and inhibiting gene expression of IL-6, IRF4, CD86 and SOCS1 in a targeted manner. Therefore, research results show that the compound FC-99 can be applied in preparing drug for preventing or treating acute hepatic failure. In the above application, dosage range for injection andoral administration is 0.01-1000mg per day, and the range can be deviated according to illness degree or dosage form difference.

The invention belongs to the technical field of the immunology, and relates to a detection kit for the severe septicopyemia and the acute liver failure. The detection kit comprises a sodium citrate contained anticoagulant tube, an erythrocyte lysate, a PBS solution, a CD45 human monoclonal antibody, a CD14 human monoclonal antibody, a CD16 human monoclonal antibody, and a 1% paraformaldehyde fixing solution. The detection kit can detect the peripheral bloods of septicopyemia and acute / acute-on-chronic liver failure patients through detecting the monocyte differentiation capability in order to determine the prognosis of the above diseases. Detection results show that the obstacles of the monocyte differentiation capability of the diseases still exist; and the peripheral blood monocyte differentiation repression is closely related with the disease prognosis because the mortality of monocyte differentiation repression patients obviously increases and the monocyte differentiation repression patients can survive after the disappearance of the differentiation repression. The detection kit provides positive meaningful reference data for further treatment schemes.

The present invention derives from the unexpected finding that necroptosis is a novel biomarker and target for therapy in patients with liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). RIPK1, MLKL or RIPK3 can be detected and quantified in serum or plasma, and used as a biomarker for outcome in ACLF and other diseases involving aberrant necroptosis. By antagonising RIPK1, MLKL or RIPK3 many of the unwanted consequences or symptoms of acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL and RIPK3 that may be used in the treatment or prevention of ACLF. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL or RIPK3 that may be used in the treatment or prevention of aberrant necroptosis in the kidney, brain, liver or other organ of the body.

The invention relates to the identification of Secreted Protein, Acidic and Rich in Cysteine (SPARC) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof an agent that inhibits at least partially the expression of SPARC and / or interferes with its biological function.

The invention provides an application of CST1 in prevention and / or treatment of liver immune disorder diseases. Specifically, the invention provides an application of a CST1 gene, or a protein thereof or an accelerant thereof, the CST1 gene, or the protein thereof or the accelerant thereof is used for preparing a composition or a preparation, and the composition or the preparation is used for preventing and / or treating liver immune disorder diseases. The invention also accidentally finds that the CST1 protein and the CST1 overexpression-based cell therapy have great potential for the treatment of acute hepatic failure.

The invention provides application of rhIL-1Ra in preparing medicaments for treating acute liver failure. Compared with a control group, the rhIL-1Ra can obviously inhibit the activity of alanine aminotransferase and aspartate aminotransferase in serum, the death of liver cells is reduced, and the proliferation of the liver cells is promoted, so that the rhIL-1Ra has obvious therapeutic effects ofprotecting liver injury and promoting liver regeneration. In addition, the rhIL-1Ra inhibits apoptosis mediated by caspase-3, caspase-8 and caspase-9 activation in liver tissue by decreasing mitochondrial cytochrome c release. In summary, the rhIL-1Ra provides a strategy for the preparation of candidate drugs capable of reducing hepatocyte apoptosis for the treatment of APAP-induced acute liver failure and liver injury.

The invention belongs to the field of medicines, and provides a medicine for treating acute liver failure. The invention discovers that a compound kinsenoside (Kinsenoside(3-(R)-3-beta-D-Glucopyranosyloxybutanolide) can effectively prevent the development of acute liver failure, and in a mouse liver failure model, the compound has the activities of improving liver function and oxidative stress injury, and reducing inflammatory factor secretion and the like; and meanwhile, hepatic cell apoptosis is inhibited by protecting the structural integrity of mitochondria, so that the compound has remarkable liver protection activity and can be used as a medicine for treating the acute liver failure for treating the acute liver failure.

The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1α) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1α) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of aberrant pyroptosis in the kidney, brain, liver or other organ of the body.

The present disclosure relates to an artificial, extracorporeal system for supporting the function of the liver of a patient suffering from liver failure, which is characterized in that it comprises a first high-flux or high cut-off hollow fiber membrane dialyzer which is perfused on the lumen side with the patient's blood and wherein a buffered aqueous solution comprising human serum albumin is passed in a continuous flow through the filtrate space of said first dialyzer, a second hollow fiber membrane dialyzer which removes water-soluble substances from the dialysate of said first dialyzer, and a third, integrated hollow fiber membrane dialyzer which is perfused with the retentate of second hemodialyzer and which allows the passage of certain amounts of albumin over the membrane wall into the filtrate space which is populated with adsorbent material. The system can be used for the treatment of acute liver failure and acute-on-chronic liver failure.

The invention provides a preparation method of hepatocyte-like cells prepared from humanized adipose-derived stem cells and an obtained hepatocyte-like cell population. The method includes the steps that in a specific induced differentiation step, a specific cell factor combination is used, and in this way, the highly-mature hepatocyte-like cells are obtained from the humanized adipose-derived stem cells and then used for treating an acute hepatic failure.

The present disclosure relates to a composition for preventing or treating acute liver failure using exosomes. The inventors of the present disclosure have experimentally identified in an acute liver failure animal model that mice to which exosomes derived from adipose-derived mesenchymal stem cells were administered survived at higher rates, had improved levels of aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) and exhibited superior apoptosis-inhibiting and anti-inflammatory effects, compared with mice to which the exosomes were not administered. Thus, the composition of the present disclosure can be usefully used for development of medical products, foods, etc. for preventing, alleviating or treating acute liver failure.

The invention relates to the field of biomedicine, and provides a Kupffer cell activity inhibitor. The activity inhibitor is a recombinant human IL-1 receptor antagonist (rhIL-1Ra). Experiments find that the rhIL-1Ra significantly inhibits the activity of large Kupffer cells with high expression of IL-1RI, and inhibits the ultrastructure and phagocytic activity of Kupffer cells, thereby inhibitingthe activity of the Kupffer cells, significantly reducing hepatocyte apoptosis and promoting liver cell proliferation. According to the above conclusions, the recombinant human IL-1 receptor antagonist (rhIL-1Ra) reduces the hepatocyte apoptosis and promotes hepatocyte regeneration by inhibiting the activity of the Kupffer cells, and provides a strategy for preparing a drug for treating acute liver failure and liver injury.

The invention discloses a pharmaceutical composition for treating Alpers-Huttenlocher syndrome, particularly drugs of the pharmaceutical composition and application of the drugs and pharmaceutical composition. The pharmaceutical composition for treating Alpers-Huttenlocher syndrome comprises sodium valproate and an anti-hepatic injury drug, wherein the anti-hepatic injury drug is selected from at least one of cyclosporin A, L-carnitine and N-acetylcysteine. The pharmaceutical composition can be used for treating Alpers-Huttenlocher syndrome, has favorable treatment effect, and is capable of obviously inhibit hepatocyte apoptosis, obviously relieving acute hepatic failure when the sodium valproate is used for treating patients with Alpers-Huttenlocher syndrome, and lowering the mortality of the patients.

The present invention relates to the preparation of poly(amino oxalate) (PAOX) using oxalyl chloride, 1,4-cyclohexanedimethanol, and piperazinediethanol, the preparation of biodegradable polymer particles using the PAOX, and the use of PAOX particles as a drug delivery vehicle. The PAOX according to the present invention is a polymer that has three characteristics of biodegradability, biocompatibility, and cationic properties at the same time with appropriate hydrophobicity and thus can be prepared as particles that allow rapid drug release. Moreover, the particles improve the delivery efficiency of a drug into cells and thus can be efficiently used as a drug delivery vehicle for the treatment of acute inflammatory diseases such as acute liver failure and acute lung injury.

The invention discloses a medicine composition for treating acute hepatic failure. Active ingredients of the medicine composition comprise Dioxasampsone A, and also comprise esculentoside D. Through being metered by weight, the ratio of the Dioxasampsone A to the esculentoside D is (1:1) to (20:1). A good effect is achieved on the treatment of acute hepatic failure when the weight ratio of the Dioxasampsone A to the esculentoside D is (8 to 11):1.

The invention relates to application of lactobacillus reuteri in preparation of a medicine for treating acute liver failure (AHF). In-depth research aiming at relieving liver and intestinal inflammation is conducted, and research objects are divided into a blank control group, a positive control group and a supplementary lactobacillus reuteri group. The result finds that the liver transaminase level, inflammatory factor IL-17 and intrahepatic inflammatory cell in the supplementary lactobacillus reuteri group are decreased, that is, the lactobacillus reuteri is supplemented every day preventively, so that liver and intestinal inflammation can be relieved when AHF occurs. In the context, it is desirable to alleviate liver and intestinal inflammation supplementing Lactobacillus reuteri preventively in healthy populations.

The present application relates to a preparation method of a curcuma oil clathrate that can be used for preventing or treating acute liver failure, the obtained curcuma oil clathrate and a pharmaceutical composition containing the same. The curcuma oil inclusion compound and pharmaceutical composition of the present application have obvious therapeutic effects on acute liver failure such as reducing mortality, reducing transaminase, inhibiting liver cell apoptosis and necrosis, and inhibiting immune inflammation damage.

The present invention discloses a preparation method of mesenchymal stem cells for treating acute liver failure. The mesenchymal stem cells with higher purity are successfully separated and cultured by using a full bone marrow wall-pasting method, the separated and cultured mesenchymal stem cells are subjected to an IL-1 beta pretreatment, during treatment, the IL-1 beta pretreatment obviously enhances expression of CXCR4 in the mesenchymal stem cells, homing capability of the mesenchymal stem cells to damaged liver is further improved, improvement effects of the mesenchymal stem cells on survival rate, liver functions, hepatic necrosis and hepatic cell apoptosis of rats with acute liver failure are obviously improved, and reconstruction of the liver is also further promoted. The mesenchymal stem cells obtained by the preparation method have excellent curative effects during treatment of the acute liver failure. The preparation method is simple in operation steps and reasonable in technical scheme, the IL-1 beta pretreatment can effectively improve the curative effects on the treatment of the acute liver failure, and the preparation method provides a new direction and a theoreticalbasis for the curative effects of the acute liver failure, and has higher practicability.

Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.